Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Reshaping human antibodies for therapy

Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565

A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal Transplants

Ortho Multicenter Transplant Study Group* (1985) · New England Journal of Medicine · doi:10.1056/nejm198508083130601 · Cited by 720

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

Hale, G., Clark, M., Marcus, R. E., Winter, G. P., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.

Han, J. S., Thompson, P., & Beutler, B. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.1.391 · Cited by 508

Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells

Lanier, L. L., Yu, G., & Phillips, J. H. (1989) · Nature · doi:10.1038/342803a0 · Cited by 436

Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1.

PERUSSIA, B., Starr, S. E., Abraham, S. R., Fanning, V., & Trinchieri, G. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.5.2133 · Cited by 409

TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH OKT3 MONOCLONAL ANTIBODY

Cosimi, A. B., Burton, R. C., Colvin, R. B., Goldstein, G., Delmonico, F. L., LaQuaglia, M. P., TOLKOFF-RUBIN, N. E., Rubin, R. H., Herrin, J. T., & Russell, P. S. (1981) · Transplantation · doi:10.1097/00007890-198112000-00018 · Cited by 389

Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA.

Arya, S. K., Wong‐Staal, F., & Gallo, R. C. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.1.273 · Cited by 387

Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells.

Anegón, I., Cuturi, M. C., Trinchieri, G., & PERUSSIA, B. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.167.2.452 · Cited by 368

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

Dyer, M. J. S., Hale, G., Hayhoe, F. G. J., & Waldmann, H. (1989) · Blood · doi:10.1182/blood.v73.6.1431.1431 · Cited by 349

Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy

Findlay, L., Eastwood, D., Ball, C., Robinson, C. J., Bird, C., Wadhwa, M., Thorpe, S. J., Thorpe, R., Stebbings, R., & Poole, S. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.06.022 · Cited by 31

Hands on Alemtuzumab-experience from clinical practice: whom and how to treat

Hassoun, L., Eisele, J., Thomas, K., & Ziemssen, T. (2016) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-016-0011-1 · Cited by 31

Virus-Induced Autoimmune Reactions in the CNS

Talbot, P. J., Arnold, D. L., & Antel, J. P. (2001) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-10356-2_12 · Cited by 30

Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial

Riechelmann, H., Wiesneth, M., Schauwecker, P., Reinhardt, P., Gronau, S., Schmitt, A., Schroen, C., Atz, J., & Schmitt, M. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0283-6 · Cited by 30

Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions

Rowley, T. F., Peters, S. J., Aylott, M. C., Griffin, R., Davies, N. L., Healy, L. J., Cutler, R. M., Eddleston, A., Pither, T. L., Sopp, J. M., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0149-9 · Cited by 29

“Cytokine storm”, not only in COVID-19 patients. Mini-review

Lukán, N. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.09.007 · Cited by 29

An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics

Reed, D. M., Paschalaki, K. E., Starke, R. D., Mohamed, N. A., Sharp, G., Fox, B. J., Eastwood, D., Bristow, A., Ball, C., Vessillier, S., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-268144 · Cited by 29

In Vitro Depletion of Tissue-Derived Dendritic Cells by CMRF-44 Antibody and Alemtuzumab: Implications for the Control of Graft-Versus-Host Disease

Collin, M. P., Munster, D. J., Clark, G. J., Wang, X., Dickinson, A. M., & Hart, D. N. J. (2005) · Transplantation · doi:10.1097/01.tp.0000149321.86104.c4 · Cited by 29

Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs

Vandivort, T. C., Horton, D. B., & Johnson, S. B. (2020) · Journal of Clinical and Translational Science · doi:10.1017/cts.2020.493 · Cited by 28

Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome

Azar, M. M., Shin, J. J., Kang, I., & Landry, M. L. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1830760 · Cited by 30

Neurologic complications in kidney transplant recipients

Piotrowski, P. C., Lutkowska, A., Tsibulski, A., Karczewski, M., & Jagodziński, P. P. (2017) · Folia Neuropathologica · doi:10.5114/fn.2017.68577 · Cited by 28

Membrane‐tethered proteins for basic research, imaging, and therapy

Cheng, T., & Roffler, S. R. (2008) · Medicinal Research Reviews · doi:10.1002/med.20127 · Cited by 28

CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond

Dumont, F. J. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.1.23 · Cited by 28

Mechanism of action of three newly registered drugs for multiple sclerosis treatment

Kasarełło, K., Cudnoch‐Jędrzejewska, A., Członkowski, A., & Mirowska-Guzel, D. M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.02.017 · Cited by 27

Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format

Hussain, K., Hargreaves, C. E., Rowley, T. F., Sopp, J. M., Latham, K. V., Bhatta, P., Sherington, J., Cutler, R. M., Humphreys, D. P., Glennie, M. J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00390 · Cited by 27

CD52 expression in non-mycotic T- and NK/T-cell lymphomas

Chang, S., Lu, C., & Chuang, S. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601016167 · Cited by 27

Cytokine release syndrome in solid tumors

Synnott, D., O’Reilly, D., de Freitas, D. G., & Naidoo, J. (2025) · Cancer · doi:10.1002/cncr.70069 · Cited by 27

Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis

Walker, M., Makropoulos, D., Achuthanandam, R., Arsdell, S. V., & Bugelski, P. J. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.06.001 · Cited by 26

The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities

Davey, A. S., Call, M. E., & Call, M. J. (2020) · Cancers · doi:10.3390/cancers13010038 · Cited by 28

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation

Pfeuffer, S., Schmidt, R., Straeten, F. A., Pul, R., Kleinschnitz, C., Wieshuber, M., Lee, D.-H., Linker, R. A., Doerck, S., Straeten, V., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9117-z · Cited by 26

Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases

Siatskas, C., Chan, J. M. K., Field, J., Murphy, K., Nasa, Z., Toh, B., & Alderuccio, F. (2006) · Current Gene Therapy · doi:10.2174/156652306775515600 · Cited by 25

Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial

Chowdhury, F. D., Johnson, P., Glennie, M. J., & Williams, A. P. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0070 · Cited by 26

Alemtuzumab for the Treatment of Relapsing–Remitting Multiple Sclerosis

Hersh, C. M., & Cohen, J. A. (2014) · Immunotherapy · doi:10.2217/imt.14.7 · Cited by 24

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Ryan, J. M., Wasser, J. S., Adler, A. J., & Vella, A. T. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1152256 · Cited by 24

POTENTIAL BIOLOGIC AGENTS FOR TREATING RHEUMATOID ARTHRITIS

Moreland, L. W. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70212-x · Cited by 23

Janus kinase inhibition in the treatment and prevention of graft-versus-host disease

Togni, E. D., Cole, O., & Abboud, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1304065 · Cited by 23

Diversity and Duplicity: Human Fcγ Receptors in Host Defense and Autoimmunity

Kimberly, R. P., Wu, J., Gibson, A., Su, K., Qin, H., Li, X., & Edberg, J. C. (2002) · Immunologic Research · doi:10.1385/ir:26:1-3:177 · Cited by 23

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis

Blasco, M. R., Ramos, A., García-Malo, C., & García‐Merino, A. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8306-x · Cited by 22

Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products

Hunter, B. D., Rogalski, M., & Jacobson, C. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1644316 · Cited by 23

The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy

Mansouri, V., Yazdanpanah, N., & Rezaei, N. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1984449 · Cited by 21

Successful Treatment of Stem Cell Graft Failure in Pediatric Patients Using a Submyeloablative Regimen of Campath-1H and Fludarabine

Ahmed, N. M., Leung, K. S., Rosenblatt, H. M., Bollard, C. M., Gottschalk, S. M., Myers, G. D., Carrum, G., Heslop, H. E., Brenner, M. K., & Krance, R. A. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.09.003 · Cited by 21

Alemtuzumab in Peripheral T-Cell Malignancies

Dearden, C. E. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/1084978041979661 · Cited by 21

Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms – Report of an international collaborative study

Vessillier, S., Fort, M. M., O’Donnell, L. M., Hinton, H. J., Nadwodny, K. L., Piccotti, J. R., Rigsby, P., Staflin, K., Stebbings, R., Mekala, D. J., et al. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100042 · Cited by 20

Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature

Zhang, Y., Wen, X., Ouyang, Y., Hu, Y., Fang, X., Zhang, J., & Yin, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24380 · Cited by 20

Alemtuzumab in the treatment of chronic lymphocytic lymphoma

Boyd, K. D., & Dearden, C. E. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.525 · Cited by 20

With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process

Crescioli, S., Jatiani, S., & Moise, L. (2025) · mAbs · doi:10.1080/19420862.2025.2453515 · Cited by 18

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

Chen, X., Li, P., Tian, B., & Kang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1079181 · Cited by 19

Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target

Abès, R., Dutertre, C., Agnelli, L., & Teillaud, J. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.57 · Cited by 18

Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma

Kang, B., Park, H., & Kim, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092302 · Cited by 18

Differential responses of CD45+ve T-cell subsets to MBP in multiple sclerosis

Ponsford, M., Mazza, G., Coad, J., Campbell, M. J., Zajicek, J., & Wraith, D. C. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01507.x · Cited by 18

Phenotypic changes with immunosuppression in human recipients

Mueller, T. (2003) · Frontiers in bioscience · doi:10.2741/1182 · Cited by 18

Review: Innovative monoclonal antibody therapies in multiple sclerosis

Linker, R. A., & Kieseier, B. C. (2008) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608093945 · Cited by 17

Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis

Soleimani, B., Murray, K., & Hunt, D. P. J. (2019) · Drug Safety · doi:10.1007/s40264-019-00799-1 · Cited by 16

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety

Jones, D., & Goldman, M. D. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.951332 · Cited by 14

Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors

Pavlova, A., Maschan, M. A., & Ponomarev, V. (2017) · Oncohematology · doi:10.17650/1818-8346-2017-12-1-17-32 · Cited by 15

The Monoclonal Antibodies Campath-1H and Rituximab in theTherapy of Chronic Lymphocytic Leukemia

Schulz, H., Winkler, U., Staak, J. O., & Engert, A. (2000) · Oncology Research and Treatment · doi:10.1159/000055001 · Cited by 15

A Mosquito AgTRIO Monoclonal Antibody Reduces Early Plasmodium Infection of Mice

Chuang, Y.-M., Tang, X.-D., & Fikrig, E. (2021) · Infection and Immunity · doi:10.1128/iai.00359-21 · Cited by 13

Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes

Nguyen, T., Havari, E., McLaren, R. P., Zhang, M., Jiang, Y., Madden, S. L., Roberts, B., Kaplan, J. M., & Shankara, S. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.623253 · Cited by 14

A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis

Morgan, A. W., Hale, G., Rebello, P., Richards, S. J., Gooi, H. C., Waldmann, H., Emery, P., & Isaacs, J. D. (2008) · QJM · doi:10.1093/qjmed/hcn006 · Cited by 14

Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies

Strohl, W. R. (2011) · Modecular medicine and medicinal · doi:10.1142/9781848166295_0005 · Cited by 13

Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non‐malignant diseases in children: A review

Guilcher, G. M. T., Shah, R. M., & Shenoy, S. S. (2018) · Pediatric Transplantation · doi:10.1111/petr.13142 · Cited by 13

Cytokine Release After Treatment With Rituximab in Renal Transplant Recipients

Kamburova, E. G., van den Hoogen, M. W. F., Koenen, H. J. P. M., Baas, M. C., Hilbrands, L. B., & Joosten, I. (2015) · Transplantation · doi:10.1097/tp.0000000000000515 · Cited by 13

Alemtuzumab for multiple sclerosis: the new concept of immunomodulation

Gallo, P., Centonze, D., & Marrosu, M. G. (2017) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-017-0024-4 · Cited by 13

Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma

Gutierrez, A. M., Rodríguez, J., Martínez, J., Amézaga, R., Ramos, R. F., Galmes, B., Bea, M. D., Ferrer, J. M., Pons, J., Sampol, A., et al. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500254752 · Cited by 12

Immune complexes inhibit apoptosis of chronic lymphocytic leukaemia B cells

Gamberale, R., Geffner, J. R., Trevani, A. S., Cherñavsky, A. C., Scolnik, M., Arrossagaray, G., Sarmiento, M. A., & Giordano, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01759.x · Cited by 12

Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.

Heiblig, M., Elhamri, M., Michallet, M., & Thomas, X. (2015) · PubMed Central · doi:10.4252/wjsc.v7.i7.1022 · Cited by 11

Recent Advances in Biotherapeutics Drug Discovery and Development

Zhong, X., Neumann, P. J., Corbo, M., & Loh, E. (2011) · InTech eBooks · doi:10.5772/28094 · Cited by 10

Nonclinical Tools to Assess Risk of Drug Hypersensitivity Reactions

Whritenour, J., Casinghino, S. R., Collinge, M., & Zhu, X. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103354 · Cited by 10

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Fuchs, E., Rudnik‐Jansen, I., Dinesen, A., Selnihhin, D., Mandrup, O. A., Thiam, K., Kjems, J., Pedersen, F. S., & Howard, K. A. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.09.048 · Cited by 9

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions

Moore, J. E., Bloom, P. C., Chu, C. C., Bruno, J. E., Herne, C. A., Baran, A. M., Quataert, S. A., Mosmann, T. R., Taylor, R. P., Wallace, D. S., et al. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107072 · Cited by 8

Obinutuzumab for B-cell malignancies

Owen, C., & Stewart, D. A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.922535 · Cited by 8

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

Alakhras, N. S., Qiu, J., Rocha, G. V., Witcher, D. R., Köester, A., You, J., Schaer, D., Holmgaard, R., Driscoll, K. E., Willy, J. A., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1474996 · Cited by 8

Different types of FC γ -receptors are involved in anti-Lewis Y antibody induced effector functions in vitro

Dettke, M., & Loibner, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0940 · Cited by 8

Assays for Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Reverse ADCC (Redirected Cytotoxicity) in Human Natural Killer Cells

PERUSSIA, B., & Loza, M. J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-044-6:179 · Cited by 8

Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia

Fabrizio, V. A., & Curran, K. J. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101305 · Cited by 7

Is an in vitro whole blood cytokine assay useful to detect the potential risk of severe infusion reaction of monoclonal antibody pharmaceuticals?

Iwata, Y., Harada, A., Hara, T., Kubo, C., Inoue, T., Tabo, M., Ploix, C. C., Manigold, T., Hinton, H. J., & Mishima, M. (2016) · The Journal of Toxicological Sciences · doi:10.2131/jts.41.523 · Cited by 7

Immunosuppression in Pancreas Transplantation

Kaufman, D. B., & Gruessner, R. W. G. (2004) · Springer eBooks · doi:10.1007/978-1-4757-4371-5_10 · Cited by 7

General Toxicity Testing and Immunotoxicity Testing for Biopharmaceuticals

Bussiere, J. L. (2007) · doi:10.1002/9780470292549.ch16 · Cited by 7

Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen

Leckey, R., Borsellino, L., Rawlings, A. M., Ashkenas, J., & Suri, A. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104030 · Cited by 6

Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux

Pallardy, M. J. (2009) · médecine/sciences · doi:10.1051/medsci/200925121130 · Cited by 6

A case of anaphylaxis to alemtuzumab

Nye, C. J. S., Wagner, A., Kousin‐Ezewu, O., Jones, J., & Coles, A. J. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09214-2 · Cited by 6

Selecting an Optimal Antibody for Antibody- Drug Conjugate Therapy

Ritchie, M. F., Bloom, L., Carven, G. J., & Sapra, P. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-13081-1_3 · Cited by 6

Hurdles to Cardioprotection in the Critically Ill

Hoe, L. E. S., Bartnikowski, N., Wells, M. A., Suen, J. Y., & Fraser, J. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153823 · Cited by 6

Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinoma

Gabeen, A. A., Fathy, S. A., El-Houseini, M. E., & Hamid, F. A. (2014) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s56012 · Cited by 6

Toxicities associated with lymphoma-targeting bispecific antibodies—a review

Doig, C., & Yannakou, C. K. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1582975 · Cited by 5

Postoperative Cardiac Tamponade After Kidney Transplantation

Adams, P. S., Shapiro, R., & Hilmi, I. A. (2013) · Transplantation · doi:10.1097/tp.0b013e31827d9757 · Cited by 5

B-cell depleting immunotherapies: therapeutic opportunities and toxicities

Bufalo, F. D., Merli, P., Alessi, I., & Locatelli, F. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1573672 · Cited by 5

In Vitro Cytokine Release Assays: Reducing The Risk of Adverse Events in Man

Kirton, C. M., Gliddon, D., Bannish, G., Bembridge, G. P., & Coney, L. (2011) · Bioanalysis · doi:10.4155/bio.11.272 · Cited by 5

Highly sensitive in vitro cytokine release assay incorporating high-density preculture

Ito, S., Miwa, K., Hattori, C., Aida, T., Tsuchiya, Y., & Mori, K. (2021) · Journal of Immunotoxicology · doi:10.1080/1547691x.2021.1984617 · Cited by 4

Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies

Madsen, N. H., Gad, M., & Larsen, J. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113231 · Cited by 4

Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.

Oribe, N., Tanimoto, T. E., Shimoda, K., Hikiji, W., Mitsugi, K., Takase, K., Henzan, H., Numata, A., Miyamoto, T., Fukuda, T., et al. (2004) · PubMed · Cited by 4

Immunotoxicology

Burns‐Naas, L. A., & Pallardy, M. J. (2013) · doi:10.1002/9781118517000.ch17 · Cited by 4

Mosunetuzumab and the Emerging Role of T-Cell-Engaging Therapy in Follicular Lymphoma

Greenfeld, S. M., & Assouline, S. E. (2023) · Future Oncology · doi:10.2217/fon-2023-0274 · Cited by 3

Alemtuzumab als neue Therapieoption der Multiplen Sklerose

Warnke, C., Kieseier, B. C., Zettl, U. K., & Hp, H. (2009) · Der Nervenarzt · doi:10.1007/s00115-009-2681-9 · Cited by 2

Immunostimulatory antibodies: Challenging the drug testing paradigm

Bhogal, N., & Combes, R. D. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.02.010 · Cited by 3

Biotherapeutic first-in-human dose selection: making use of preclinical markers

Johnson, D. E. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.5 · Cited by 3

Genetic Influences on Treatment Response in Rheumatoid Arthritis

Bridges, S. L., & Kimberly, R. P. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-239-5_2 · Cited by 3

The blood endothelial cell chamber – An innovative system to study immune responses in drug development

Stančič, B., Qvarfordt, B., Berglund, M. M., Brenden, N., Sydow‐Báckman, M., Fransson, M. E., Nordling, S., & Magnusson, P. U. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107237 · Cited by 3

Differentiation between Desired Immunomodulation and Potential Immunotoxicity

Bussiere, J. L., & Mounho, B. J. (2008) · doi:10.1002/9780470386385.ch14 · Cited by 3

Relevant Immune Tests across Different Species and Surrogate Models

Bussiere, J. L. (2008) · doi:10.1002/9780470386385.ch15 · Cited by 3

Response to: S. Sega-Jazbec et al.: “Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis” Multiple Sclerosis and Related Disorders 2017

Thomas, K., & Ziemssen, T. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.08.001 · Cited by 3

Circulating immunoglobulins and transient lymphocytopenia in a sub-study of CAPRISA 012B, testing HIV monoclonal antibodies in a phase 1 trial

Sobia, P., Mahomed, S., Sivro, A., Paul, S., Osman, F., Harkoo, I., Garrett, N., Karim, Q. A., Karim, S. S. A., & Archary, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-63902-2 · Cited by 2

Systemic Inflammatory Response Post Alemtuzumab and Low‐Dose Total Body Irradiation in Pediatric Patients With Sickle Cell Disease: A Case Series

Chok, R., Girgulis, K., Nickel, R. S., & Guilcher, G. M. T. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31448 · Cited by 2

Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia

Lin, T. S., Lucas, M. S., & Byrd, J. C. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-412-2_15 · Cited by 2

Vasculitis and Biologic Infusion Therapies

Sejismundo, L. P. (2006) · Journal of Infusion Nursing · doi:10.1097/00129804-200609000-00006 · Cited by 2

Aspects of Isotype Selection

Kaymakcalan, Z., Ibraghimov, A. R., Goodearl, A. G., & Salfeld, J. G. (2010) · Springer eBooks · doi:10.1007/978-3-642-01144-3_19 · Cited by 2

Different players generate positive responses in two in vitro cytokine assay formats with aqueous and immobilized TGN1412 analog

Iwata, Y., Harada, A., Kubo, C., Inoue, T., Tabo, M., & Mishima, M. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.125 · Cited by 2

Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care

Khazal, S. J., & Mahadeo, K. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-74698-2_200-1 · Cited by 2

Monoclonal Antibody Therapy in Lymphoid Leukemias

Lin, T. S., & Byrd, J. C. (2004) · Advances in pharmacology · doi:10.1016/s1054-3589(04)51006-2 · Cited by 2

The Nonclinical Evaluation of Biotechnology‐Derived Pharmaceuticals, Moving on after the TeGenero Case*

van der Laan, J. W., Herberts, C. A., Jones, D., Thorpe, S. J., Stebbings, R., & Thorpe, R. (2014) · doi:10.1002/9783527676965.ch9 · Cited by 2

Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset

Barakonyi, A., Rabot, M., Marie‐Cardine, A., Aguerre‐Girr, M., Polgár, B., Schiavon, V., Bensussan, A., & Bouteiller, P. P. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5349 · Cited by 113

CD16 Stimulation Induces Stronger Accumulation of Cytokine mRNA in Natural Killer Cells than in Non-MHC-Restricted T Lymphocytes

Uciechowski, P., Gessner, J. E., Schindler, R., & Schmidt, R. E. (1992) · Springer eBooks · doi:10.1007/978-3-642-48715-6_45

Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding.

Aramburu, J. F., Azzoni, L., Rao, A., & PERUSSIA, B. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.3.801 · Cited by 139

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

Fauriat, C., Long, E. O., Ljunggren, H., & Bryceson, Y. T. (2009) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 894

Fc gamma RIIIA-mediated signaling involves src -family lck in human natural killer cells.

Pignata, C., Prasad, K. V. S., Robertson, M. J., Levine, H., Rudd, C. E., & Ritz, J. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.12.6794 · Cited by 59